Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234

Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The design of novel β-lactamase inhibitors is of paramount importance. Here, three novel diazabicyclooctanes (DBOs), WCK 5153, zidebactam (WCK 5107)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Chem
Main Authors: Papp-Wallace, Krisztina M., Nguyen, Nhu Q., Jacobs, Michael R., Bethel, Christopher R., Barnes, Melissa D., Kumar, Vijay, Bajaksouzian, Saralee, Rudin, Susan D., Rather, Philip N., Bhavsar, Satish, Ravikumar, Tadiparthi, Deshpande, Prasad K., Patil, Vijay, Yeole, Ravindra, Bhagwat, Sachin S., Patel, Mahesh V., van den Akker, Focco, Bonomo, Robert A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6131718/
https://ncbi.nlm.nih.gov/pubmed/29627985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b00091
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados